National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$57.95
add to cart

Rights & Permissions

topleft topright

Multiple Sclerosis: Current Status and Strategies for the Future (2001)
Institute of Medicine (IOM)

Citation Manager

. "Appendix E: Drugs Used in the Treatment of MS." Multiple Sclerosis: Current Status and Strategies for the Future. Washington, DC: The National Academies Press, 2001.

Please select a format:

BibTeX EndNote RefMan


Page
388
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Page 388

APPROVED DISEASE-MODIFYING MEDICATIONS

Generic Name

Trade Name

Company

Indication

Mechanism of Action

Potential Side Effects

Beta-Interferon-1a

Avonex, Rebifa

Biogen, Serono

RRMS

Beta-interferon-1a is believed to suppress the autoimmune destruction of myelin. Slows accumulation of disability and decreases the frequency of clinical exacerbations. Interferon-β-1a is involved in the regulation of activation, proliferation, migration, and suppressor cell function of T-cells, the modulation of the production of cytokines, including down-regulation of proinflammatory cytokines and up-regulation of inhibitory, antiinflammatory cytokines.

Flu-like symptoms, muscle aches, fever, chills and weakness, pain from intramuscular injection

Beta-Interferon-1b

Betaseron

Berlex Labs (Distributor)

Chiron (Manufacturer)

RRMS

Possesses both antiviral and immunoregulatory activities, mediated through interactions with specific cell receptors, which results in the expression of interferon-induced gene products.

Redness, pain and swelling and discoloration at injection site, flu-like symptoms, depression, anxiety, depersonalization, suicide attempts

Page
388